Physician profile
Travis W Davis
NPI 1669590477
$3,974.12
in general payments reported to CMS, 2019-2025
32 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $386 · 2021: $673 · 2022: $712 · 2023: $895 · 2024: $503 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,624.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $587.97 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $575.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $397.28 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $396.90 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.43 | 2019-2023 | Tradjenta, Jardiance, Synjardy |
| Exact Sciences Corporation | $173.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $173.24 | 2019-2024 | Krystexxa, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $162.40 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.72 | 2020-2025 | Xifaxan |
| Dexcom, INC. | $132.44 | 2021-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $128.41 | 2021-2025 | Ubrelvy |
| Abbott Laboratories | $127.09 | 2023-2025 | Freestyle Libre 3, Triclip, Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $106.47 | 2022-2023 | |
| Pfizer INC. | $95.37 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.75 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $61.04 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $47.36 | 2019-2022 | |
| Shield Therapeutics INC | $38.82 | 2022-2025 | |
| Daiichi Sankyo INC. | $35.53 | 2021-2023 | Injectafer |
| Insmed, INC. | $34.53 | 2020-2021 | |
| Esperion Therapeutics, INC. | $31.98 | 2020-2021 | |
| Allergan, INC. | $24.90 | 2019 | |
| Lundbeck LLC | $22.82 | 2020 | |
| Exeltis, USA INC. | $21.00 | 2024 | Slynd |
| Cranial Technologies, INC | $17.54 | 2024 | Doc Band |
| Janssen Pharmaceuticals, INC | $17.53 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.54 | 2025 | Caplyta |
| Shire North American Group INC | $14.84 | 2019 | |
| Eisai INC. | $14.68 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.27 | 2023 | Gvoke Hypopen |
| Adlon Therapeutics L.P. | $13.08 | 2020 | |
| Supernus Pharmaceuticals, INC. | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.